Application
Western blot analysis of anti-PARK2 (Parkin) Antibody (N-term) in NCI-H460 cell line lysates (35ug/lane). PARK2 (Parkin)(arrow) was detected using the purified Pab.Application
Parkin Antibody (N-term) flow cytometric analysis of NCI-H460 cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.Application
Confocal immunofluorescent analysis of Parkin Antibody (N-term)(Cat#AP6402a) with NCI-H460 cell followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green).Actin filaments have been labeled with Alexa Fluor 555 phalloidin (red).DAPI was used to stain the cell nuclear (blue).Application
Parkin Antibody (N-term) (AP6402a)immunohistochemistry analysis in formalin fixed and paraffin embedded human brain tissue followed by peroxidase conjugation of the secondary antibody and DAB staining.This data demonstrates the use of Parkin Antibody (N-term) for immunohistochemistry. Clinical relevance has not been evaluated.| Product Name | Parkin Antibody (N-term) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | PARK2; PRKN; E3 ubiquitin-protein ligase parkin; Parkinson juvenile disease protein 2 |
| Clonality | Polyclonal |
|---|---|
| Isotype | Ig |
| Host Species | Rabbit |
| Tested Applications | WBFCIFIHC |
| WB:1:100~500 FC |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Gene Synonyms | PRKN |
|---|---|
| Alternative Names | PARK2 PRKN E3 ubiquitin-protein ligase parkin Parkinson juvenile disease protein 2 |
| Molecular Weight(MW) | 51641 Da |
| Function | Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins, such as BCL2, SYT11, CCNE1, GPR37, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP, SEPT5, ZNF746 and AIMP2. Mediates monoubiquitination as well as 'Lys-48'-linked and 'Lys-63'-linked polyubiquitination of substrates depending on the context. Participates in the removal and/or detoxification of abnormally folded or damaged protein by mediating 'Lys-63'-linked polyubiquitination of misfolded proteins such as PARK7: 'Lys-63'- linked polyubiquitinated misfolded proteins are then recognized by HDAC6, leading to their recruitment to aggresomes, followed by degradation. Mediates 'Lys-63'-linked polyubiquitination of SNCAIP, possibly playing a role in Lewy-body formation. Mediates monoubiquitination of BCL2, thereby acting as a positive regulator of autophagy. Promotes the autophagic degradation of dysfunctional depolarized mitochondria. Mediates 'Lys-48'-linked polyubiquitination of ZNF746, followed by degradation of ZNF746 by the proteasome; possibly playing a role in role in regulation of neuron death. Limits the production of reactive oxygen species (ROS). Loss of this ubiquitin ligase activity appears to be the mechanism underlying pathogenesis of PARK2. May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity. May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. Regulates cyclin-E during neuronal apoptosis. May represent a tumor suppressor gene |
| Tissue Specificity | Highly expressed in the brain including the substantia nigra. Expressed in heart, testis and skeletal muscle Expression is down-regulated or absent in tumor biopsies, and absent in the brain of PARK2 patients. Overexpression protects dopamine neurons from kainate-mediated apoptosis. Found in serum (at protein level) |
| Cellular Localization | Cytoplasm, cytosol. Nucleus. Endoplasmic reticulum. Mitochondrion. Note=Mainly localizes in the cytosol Co-localizes with SYT11 in neutrites. Co-localizes with SNCAIP in brainstem Lewy bodies. Relocates to dysfunctional mitochondria that have lost the mitochondrial membrane potential; recruitment to mitochondria is PINK1-dependent |
Application
Western blot analysis of anti-PARK2 (Parkin) Antibody (N-term) in NCI-H460 cell line lysates (35ug/lane). PARK2 (Parkin)(arrow) was detected using the purified Pab.
Application
Parkin Antibody (N-term) flow cytometric analysis of NCI-H460 cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.
Application
Confocal immunofluorescent analysis of Parkin Antibody (N-term)(Cat#AP6402a) with NCI-H460 cell followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green).Actin filaments have been labeled with Alexa Fluor 555 phalloidin (red).DAPI was used to stain the cell nuclear (blue).
Application
Parkin Antibody (N-term) (AP6402a)immunohistochemistry analysis in formalin fixed and paraffin embedded human brain tissue followed by peroxidase conjugation of the secondary antibody and DAB staining.This data demonstrates the use of Parkin Antibody (N-term) for immunohistochemistry. Clinical relevance has not been evaluated.| Application Notes | WB:1:100~500 FC |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS. |
Data sheet for OM216467